(Q28245986)

1

0 references

Khader Mustafa

2

0 references

Ghaleb Sweis

3

0 references

Ray Sawaqed

4

0 references

Khaldoon Alawneh

5

0 references

Rafah Salloum

6

0 references

Maria Badaracco

7

0 references

Nadera J Sweiss

Expert Opinion on Biological Therapy

9

0 references

language of work or name

English

0 references

publication date

July 2009

0 references

published in

0 references

volume

9

0 references

issue

7

0 references

page(s)

889-95

0 references

cites work

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

1 reference

https://api.crossref.org/works/10.1517/14712590903018837

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/14712590903018837

B-cell targeting: a novel approach to immune intervention today and tomorrow

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712590903018837

Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903018837

Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903018837

Invited article: inhibition of B cell functions: implications for neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903018837

Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903018837

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903018837

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903018837

New approaches of B-cell-directed therapy: beyond rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903018837

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903018837

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903018837

Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903018837

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903018837

Chemokines and their receptors in rheumatoid arthritis: future targets?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903018837

Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903018837

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903018837

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903018837

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903018837